By David Tuller, DrPH Last week, two major articles on long Covid appeared in well-known US publications, one in the Atlantic, the other in Vox. Like the New York Times Magazine article that ran in January, these stories addressed with nuance the complex and unclear relationship between the varieties of ...

By David Tuller, DrPH The Journal of Pyschosomatic Research, a high-profile publication from Elsevier, has recently published an article relevant to long-standing arguments about trials that are both unblinded and reliant on subjective outcomes--like, say, the PACE study and related research into psycho-behavioral treatments for ME/CFS. This specific question--how to ...

By David Tuller, DrPH Tracie White, a science writer at Stanford University, first stumbled across the story of Whitney Dafoe as an assignment from one of her editors. That initial encounter ultimately turned into The Puzzle Solver: A Scientist's Desperate Quest to Cure the Illness that Stole His Son, an ...

By David Tuller, DrPH The US government seems to be taking Long COVID seriously. In December, Congress allocated $1.15 billion over four years for research into the issue. This week, Francis Collins, director of the National Institutes of Health, announced the agency's plans for that funding. (I've posted his announcement ...

By David Tuller, DrPH It's been ten years since The Lancet published the first results of the PACE trial. Wow! Ten years ago, I was 54 and still a graduate student in public health at UC Berkeley. I was also busy writing stories for The New York Times about the ...